Connect with us

Technology

Investors Eye Biotech Sector as Cancer Therapy Market Surges

Published

on

USA News Group News Commentary
Issued on behalf of Oncolytics Biotech Inc.

VANCOUVER, BC, Feb. 19, 2025 /PRNewswire/ — USA News Group News Commentary – Amid the excitement surrounding Project Stargate—the $500 billion investment aimed at revolutionizing AI-driven data centers—concerns over the rising global cancer rates, particularly among younger populations, remain pressing. Lifestyle factors are increasingly under scrutiny, with the World Health Organization (WHO) now advocating for cancer warning labels on alcohol products. Despite these alarming trends, several biotech companies have already made notable strides in 2025, with recent advancements coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), GRAIL, Inc. (NASDAQ: GRAL), Quest Diagnostics Incorporated (NYSE: DGX), Renovaro Inc. (NASDAQ: RENB), and Predictive Oncology Inc. (NASDAQ: POAI).

The article continued: The Center for Innovation and Translation of Point of Care Technologies for Equitable Cancer Care (CITEC) has launched a global initiative focused on accelerating next-generation cancer detection technologies. With demand for advanced oncology solutions increasing, industry projections suggest significant market expansion, as DelveInsight Business Research forecasts a 9.12% compound annual growth rate (CAGR)—pushing the global cancer therapy market to an estimated $285.96 billion by 2030.

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage company focused on immunotherapy for cancer, continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep’s potential in hard-to-treat cancers. Oncolytics was pleased to highlight two significant developments for its immunotherapy, pelareorep: the safety and regulatory clearance to advance enrollment in its pancreatic cancer study and the recent presentation of new efficacy and safety data at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in late January.

“We’re hitting critical milestones that validate our progress and set the stage for what we believe will be an exciting year,” said Wayne Pisano, Interim CEO and Chair of Oncolytics’ Board of Directors. “With positive feedback from regulators in place, we’re advancing our pancreatic cancer study toward full enrollment, and our ASCO GI presentations highlighted pelareorep’s strong safety and efficacy results in two hard-to-treat cancers. We remain focused on bringing new treatment options to patients while creating value for shareholders as we move forward in 2025.”

Germany’s Paul-Ehrlich-Institute (PEI) has granted Oncolytics Biotech approval to proceed with full enrollment in its pancreatic cancer trial (GOBLET Cohort 5) following a successful safety review. This milestone allows the study to advance as planned, with 30 patients set to participate in Stage 1 across two treatment arms evaluating pelareorep in combination with modified FOLFIRINOX, with or without atezolizumab. With the safety run-in complete, Oncolytics will continue gathering safety data, with an initial efficacy readout expected later this year. This progress reinforces pelareorep’s potential in one of the most aggressive and challenging-to-treat cancers, bringing the company one step closer to expanding its clinical impact in gastrointestinal oncology.

At ASCO GI 2025, Oncolytics Biotech presented new clinical data reinforcing pelareorep’s potential in two difficult-to-treat cancers: anal and pancreatic cancer. In anal cancer, patients receiving pelareorep + atezolizumab continue to show stronger-than-expected responses, outperforming results seen in published studies using checkpoint inhibitors alone. In pancreatic cancer, pelareorep has previously demonstrated a strong efficacy signal in combination with gemcitabine, nab-paclitaxel, and atezolizumab. The latest findings confirm a favorable safety profile when using pelareorep with a different chemotherapy regimen (modified FOLFIRINOX), with and without atezolizumab, potentially broadening its clinical applications. These results further de-risk pelareorep’s development and could support the advancement into larger, registration-enabling trials, bringing the therapy closer to addressing major unmet needs in gastrointestinal oncology.

As Oncolytics moves into a pivotal year, multiple high-impact milestones are set to shape the company’s progress. Upcoming data readouts from ongoing gastrointestinal cancer trials will provide further insights, including translational results that help characterize pelareorep’s mechanism of action. Additionally, regulatory interactions throughout the year could play a crucial role in accelerating future trials, bringing pelareorep closer to potential registration-enabling studies in both breast and gastrointestinal cancers. These milestones position Oncolytics for continued momentum as it advances its clinical pipeline toward broader patient impact.

“We’re seeing clinical validation across multiple studies,” added Pisano. “With encouraging regulatory interactions in hand and data readouts ahead, 2025 is shaping up to be an exciting year for Oncolytics and our investors. As we have shown in GOBLET, BRACELET-1, and numerous previous studies, pelareorep has a favorable safety profile and efficacy signals across multiple indications with a high unmet need. We are excited about the potential for moving to a registration-enabling study in breast cancer and advancing our clinical program in gastrointestinal cancers.”

CONTINUED… Read this and more news for Oncolytics Biotech at:  https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ 

In other recent industry developments and happenings in the market include:

GRAIL, Inc. (NASDAQ: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, and Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, recently announced the initial phase of a program to improve provider access to GRAIL’s Galleri® multi-cancer early detection (MCED) test. 

Providers can now order the Galleri test directly from GRAIL through the Quest Diagnostics connectivity system. The Quest Diagnostics connectivity system enables providers in the United States to order and receive reports of laboratory tests electronically through Quest’s Quanum laboratory portal and more than 900 electronic health record (EHR) systems. More than 500,000 providers used the Quest connectivity system last year.

“Quest Diagnostics and GRAIL share a commitment to improving access to cancer screening and have worked productively together to enable patient access to GRAIL’s Galleri test via Quest’s phlebotomy network since 2021,” said Mark Gardner, Senior Vice President, Molecular Genomics and Oncology for Quest Diagnostics. “Integrating GRAIL’s Galleri test into the Quest connectivity system is the next step in this collaboration. We expect it to increase patient access by giving Quest’s provider clients the ability to seamlessly order the test through Quest, same as they do for other blood work. This collaboration brings to life the tremendous value of Quest’s ability to scale diagnostic innovation to make it accessible for all.”

Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, recently announced it entered into a binding LOI to acquire Predictive Oncology Inc. (NASDAQ: POAI) in an all-stock transaction.

By leveraging Predictive Oncology’s extensive biobank of 150,000 tumor samples, Renovaro gains a critical resource to accelerate biomarker discovery, optimize clinical trials, and enhance decision-support tools across multiple cancer types. The combined organization will operate a state-of-the-art, CLIA, NYSDOH, and CA-certified laboratory staffed by an experienced team, streamlining diagnostic test development and validation while expanding market reach in Europe. Additionally, Renovaro introduces a novel in vivo chemosensitivity and resistance assay, improving cancer treatment predictions for European patients and enabling multi-omic collaborations for drug discovery.

“We recognize that by integrating Predictive Oncology’s AI-driven drug discovery platform and vast biobank of more than 150,000 patient tumor samples, 200,000 pathology slides and decades of longitudinal drug response data with Renovaro’s multi-disciplinary artificial intelligence, multi-omics and multi-modal data expertise, we are opening to door to diagnostic, therapeutic and drug discovery possibilities that we otherwise would never have considered,” said Raymond Vennare, CEO of Predictive Oncology.

In the long term, this partnership lays the foundation for a global point-of-care cancer solution, integrating Predictive Oncology’s AI-driven small molecule solid tumor expertise with Renovaro’s AI-powered liquid biopsy and cancer vaccine programs. This first-in-class, full-stack clinical service has the potential to advance cancer therapy at every stage—from early detection and diagnostics to personalized treatment and biomarker discovery—ultimately improving patient outcomes and reducing costs.

“Renovaro is on a quest to offer cancer patients early diagnostic options, treatment protocols, and recurrence monitoring,” said David Weinstein, CEO of Renovaro. “Predictive Oncology will enhance our capabilities by assisting oncologists with patient specific diagnostic and therapeutic clinical support data. Predictive Oncology’s proprietary AI/ML platform has been proven to predict tumor-drug response with 92% accuracy which, I believe, will allow us to launch as a decision support platform for medical oncologists in 2025. As importantly, there are strong synergies with Predictive’s small molecule solid tumor drug-tumor response modeling capabilities and Renovaro’s liquid biopsy approach to early cancer detection and monitoring.”

Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ 

CONTACT:
USA NEWS GROUP
info@usanewsgroup.com
(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Logo – https://mma.prnewswire.com/media/2603685/5175129/USA_News_Group_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/investors-eye-biotech-sector-as-cancer-therapy-market-surges-302380340.html

Continue Reading

Technology

Tata Communications to Build India’s AI Super Highway

Published

on

By

Planned USD 400 – 450 million investment to create 10,000 km of AI-ready connectivity infrastructure linking India’s key data center and AI hubs

NEW DELHI, Oct. 29, 2026 /PRNewswire/ — Tata Communications, a leading global communications technology player, today announced strategic investments of close to USD 450 million to build an AI super highway in India – a high-speed, low-latency network fabric connecting India’s key AI data-centre corridors. The company will build around 10,000 kilometers of the new long-haul fiber across India, creating one of the country’s largest AI-ready connectivity network. Integrated with Tata Communications’ global network backbone, the AI super highway will provide customers with a seamless, end-to-end connectivity fabric, supporting the performance, resilience and scale required for next-generation AI workloads.

India’s data centre industry is poised for significant growth in the near future, driven by accelerating cloud adoption, AI deployment, increasing data localisation requirements, and growing enterprise demand for resilient, high-capacity digital infrastructure. As data centre capacity expands rapidly across the country, connectivity is becoming as critical as compute power and energy availability in enabling the next generation of digital services.

Rupesh Chokshi, Chief Product and Technology Officer, Executive Vice President & Global Business Head – Network Services, Tata Communications, said, “The AI economy needs more than compute. It needs a network built for speed, scale and resilience. Tata Communications has long played a foundational role in enabling India’s digital economy, and our AI Network Fabric builds on that legacy. Our AI Network Fabric will give our global customers the ultra-low-latency, high-capacity and resilient connectivity they need to scale AI with confidence. By connecting India’s AI and data center hubs to the world, we are enabling our customers to grow and helping fuel India’s next chapter of economic growth.”

The investment aims to strengthen India’s emergence as a global AI and cloud connectivity gateway, intending to meet the unprecedented demand from hyperscale and neocloud providers, AI workloads, digital-native businesses, Global Capability Centres (GCCs), enterprises and emerging cloud platforms. It will enable global hyperscalers, digital platforms and multinational enterprises to scale their operations in India with confidence as the country enters its next phase of digital transformation.

The first phase of the program will focus on the Mumbai-Pune-Hyderabad-Chennai corridor, one of India’s most important AI and hyperscale growth routes. Subsequent phases will expand connectivity into emerging East Coast and Western India data centre ecosystems, including Vizag, Bhubaneswar, Jamnagar, GIFT City and other strategic locations. By linking the key AI corridors and data centre clusters with international cable landing stations, Tata Communications will enable seamless connectivity between India and major global AI hubs across, positioning India as a strategic gateway in the global digital infrastructure landscape.

In parallel, Tata Communications will continue to support existing enterprise and data centre connectivity requirements by scaling its current National Long Distance and metro network footprint, ensuring continued support for current growth while building capacity for future demand.

 

SOURCE Tata Communications

Continue Reading

Technology

HFE & AI 2026: TÜV Rheinland Advocates Human Factors Research Across Full Product Development Cycle

Published

on

By

Independent human factors evidence should shape design from day one — not just confirm it at the end.

BEIJING, Oct. 28, 2026 /PRNewswire/ — On October 17, 2026, TÜV Rheinland Greater China (“TÜV Rheinland”) attended the 2026 International Conference on Human Factors Engineering and Intelligent System Interaction (HFE & AI 2026) in its capacity as an independent third-party human factors research laboratory and delivered a featured talk. Centered on the theme “Collaborative Intelligence: Human Factors Engineering and the Future of Work,” the conference engaged in deep exchanges around fundamental research, key technologies, and major applications of human factors engineering in the AI era, focusing on human–computer interaction and the integration of humans with intelligent agents. Across 38 parallel sessions, the event supported the cultivation of new quality productive forces and high-quality economic development.

The conference’s smart home session, organized by Haier Innovation Design Center, also featured Huawei, Microsoft China, vivo and GoerTek. The lineup pointed to a wider industry move away from single-device performance and toward interaction that is natural, comfortable and trustworthy across devices, scenarios and intelligent systems.

Mia Xie, Ph.D., a human factors expert in TÜV Rheinland Greater China Electrical presented “From Parameters to Experience: How Human Factors Research Truly Enters Smart Product Development.” Her subject: how development teams can hear users earlier and more effectively when specifications alone no longer predict experience.

The competitive landscape for smart products is being reshaped. In the past, superior technical specifications—such as higher resolution, wider color gamuts, lower latency, or greater brightness—translated directly into a better user experience. Today, even when key parameters are nearly identical, the actual user experience can still differ markedly. User experience is the combined result of multiple interacting factors: product characteristics, specific tasks, usage environments, and individual differences.

TÜV Rheinland advocates that R&D decisions must move beyond “what technology can achieve” to focus on “what is worth achieving,” emphasizing that independent human factors research provides perceptible, measurable, and trustworthy objective evidence to support sound decision-making. In her presentation, Dr. Xie stressed that human factors research should not merely serve as “user testing” near product completion. By that stage, product architecture, technology routes, and core design solutions are typically locked in, leaving limited room for optimization. As an independent laboratory, TÜV Rheinland supports embedding human factors research earlier and more continuously throughout the development process:

Product definition, translating goals such as “a better experience” into specific, measurable human factors targetsTechnology selection, assessing whether competing technology routes deliver genuine user valueDesign and prototype iteration, comparing the experience gains, trade-offs and key influencing factors of alternative conceptsFinal verification, confirming the experience holds across users, scenarios and conditions of use

AI image enhancement shows why. Better algorithm scores do not guarantee a better picture to the viewer: processing traces, an unnatural look, artifacts or over-smoothing can cancel out the technical gain. The same applies to smart cockpits, augmented and virtual reality headsets, wearables and smart home devices. The commercial question is where users start to notice an improvement and where further investment stops paying for itself.

“As an independent, third-party laboratory, our role is not only to evaluate finished products, but to help industry build human factors research into development itself,” Xie said. “We want research findings to become reusable evidence — evidence that supports better products and, over time, better standards.”

When user experience is consistently measurable, clearly explainable, and reliably reproducible, research findings deliver value well beyond individual projects—evolving into reusable testing methodologies, product evaluation standards, and the groundwork for future certification. As smart products increasingly adapt in real time, the core industry question moves away from “what is the best setting” toward “what is the right setting for this user, at this moment, within this specific scenario.”

About TÜV Rheinland

TÜV Rheinland is a leading provider of testing, inspection and certification services worldwide. For over 150 years, the company has helped make the world a safer place. Today, more than 29,000 employees test, inspect and certify products, plants and processes, while also providing training for people in a wide range of professions. Operating from 500 locations in more than 50 countries, TÜV Rheinland helps safeguard key areas of business and everyday life. Headquartered in Cologne and generating annual revenue of close to €3 billion, the company plays a key role in quality assurance worldwide. TÜV Rheinland has been a member of the UN Global Compact since 2006, demonstrating its commitment to anti-corruption and sustainability.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/hfe–ai-2026-tuv-rheinland-advocates-human-factors-research-across-full-product-development-cycle-302922927.html

SOURCE TUV Rheinland Greater China

Continue Reading

Technology

Unleash Your Edge: ZHITAI Joins Forces with Phantom Blade Zero in Global Strategic Partnership

Published

on

By

BEIJING, Oct. 29, 2026 /PRNewswire/ — ZHITAI, the consumer memory brand of YMTC, announced a strategic partnership with Phantom Blade Zero, the highly anticipated AAA action game that has captured global attention. Under the theme “Unleash Your Edge,” the two brands have joined forces to introduce the ZHITAI × Phantom Blade Zero Collaboration Gift Box, combining high-performance memory technology with Eastern wuxia aesthetics to deliver an immersive experience in the Phantom World for gamers around the world.

With its distinctive Kungfu-punk aesthetic and intense, fast-paced combat, Phantom Blade Zero has emerged as one of the year’s most anticipated AAA action titles. The partnership’s theme, “Unleash Your Edge,” draws inspiration from the game’s protagonist, Soul, and his unwavering resolve in the face of adversity. This theme bridges the game’s lightning-fast combat with ZHITAI’s relentless pursuit of peak storage performance—reflecting both Soul’s unyielding conviction and ZHITAI’s dedication to continuous innovation and exploration.

As the official designated global memory partner of Phantom Blade Zero, ZHITAI is committed to providing professional, high-performance storage solutions. Drawing on years of technological expertise, ZHITAI aims to bring gamers worldwide a smooth, responsive storage experience that lets them fully immerse themselves in their martial arts adventures.

To further enhance the experience of exploring the Phantom World, the Collaboration Gift Box houses the ZHITAI TiPlus9100 SSD. Powered by next-gen YMTC Xtacking® 4.0 TLC NAND flash, the TiPlus9100 supports PCIe 5.0 and delivers sequential read speeds of up to 12,000 MB/s and sequential write speeds of up to 10,700 MB/s. Its DRAM-less architecture and single-sided PCB design offer versatile compatibility across gaming laptops, ultrabooks, and DIY desktops. For AAA games such as Phantom Blade Zero, where fast-paced combat and seamless scene transitions are essential to the gaming experience, the TiPlus9100 delivers stable performance under demanding workloads while helping reduce loading times and delays during scene transitions. This allows players to stay focused on every move and every moment of combat, fully immersed in the Phantom World.

Crafted for gamers, the ZHITAI × Phantom Blade Zero Collaboration Gift Box brings the Phantom World to life. Defined by a dark wuxia aesthetic, it offers an immersive unboxing experience—combining high-performance storage, custom setup accessories, and exclusive collectibles. The box houses five custom items adorned with co-branded artwork: a ZHITAI TiPlus9100 SSD with a themed sleeve, a storage box, a screwdriver, a metal sticker, and a lenticular card. By translating the Phantom Blade Zero universe into functional and collectible gear, ZHITAI seamlessly bridges high-performance hardware with the player’s personal gaming space.

From PC hardware to collectible accessories, this collaboration goes beyond bringing together high-performance memory technology and AAA action gaming. It reflects ZHITAI’s ongoing commitment to combining technological innovation with gaming culture. Through its partnership with Phantom Blade Zero, ZHITAI aims to further strengthen its presence among gamers worldwide, bringing advanced memory technology and high-quality products to a broader global audience. Looking ahead, ZHITAI will continue to explore new opportunities across international markets, delivering innovative memory solutions that meet the evolving needs of consumers around the world.

The ZHITAI × Phantom Blade Zero Collaboration Gift Box is coming soon, with further details on its launch date and availability to be announced. Stay tuned to ZHITAI’s official channels for the latest updates.

About ZHITAI

Founded on September 21, 2020, ZHITAI was launched as the flagship consumer brand of YMTC. Born from a passion for innovation and discovery, ZHITAI embodies our commitment to bringing trustworthy, cutting-edge experiences to users worldwide. Powered by a youthful energy and a deeply user-centric approach, we are defined by our long-term vision to constantly redefine what’s possible in memory technology.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/unleash-your-edge-zhitai-joins-forces-with-phantom-blade-zero-in-global-strategic-partnership-302922935.html

SOURCE ZHITAI

Continue Reading

Trending